Shots:
- The EC has approved Kostaive (ARCT-154) for active immunization to prevent COVID-19 in subjects of age ≥18yrs in the EU & EEA states following CHMP positive opinion in Dec 2024
- Approval was based on Kostaive’s clinical data incl. P-I/II/III showing its efficacy & tolerability, plus P-III COVID-19 booster trial depicting superior immunogenicity vs mRNA comparator. Also, follow-up analysis of booster dose showed higher immunogenicity & antibody response for ~12mos. in adults
- Kostaive is a self-amplifying mRNA vaccine that codes for the SARS-CoV-2 spike protein to provide active immunization against COVID-19
Ref: Prnewswire | Image: CSL & Arcturus
Related News:- Arcturus and Meiji Seika Pharma Report the EMA’s Positive Opinion of Kostaive for COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
